secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0001193125-25-148897
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 3.02
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma to issue 625,000 shares upon achieving CAR T-cell clinical milestone
--------------------------------------------------------------------------------

- Milestone for ImmPACT's next-gen CAR T-cell candidate achieved on June 20, 2025.
- 625,000 shares of common stock (post-1-for-20 reverse split) to be issued to ImmPACT securityholders.
- Shares issued in private placement exempt under Section 4(a)(2) of the Securities Act.
- Issuance is contingent consideration from the previously completed ImmPACT Bio merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000119312525148897/0001193125-25-148897-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000119312525148897/d917552d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-148897

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer